Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

GHRP-6

Growth Hormone Releasing Peptide-6, Growth hormone-releasing hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2

Quick Stats
Studies 702
Trials 0
Score 2
2014 pubmed 15 citations

Preventive effect of rikkunshito on gastric motor function inhibited by L-dopa in rats.

Wang. Lixin L; Mogami. Sachiko S; Karasawa. Hiroshi H; Yamada. Chihiro C; Yakabi. Seiichi S; Yakabi. Koji K; Hattori. Tomohisa T; Taché. Yvette Y

Key Findings

  • s‑model rats.",
  • ,

Practical Outcomes

  • For biohackers, this suggests that GHRP‑6 can blunt ghrelin‑related benefits such as improved stomach emptying. It highlights a potential interaction: using GHRP‑6 may counteract agents that rely on ghrelin signaling. However, the study is in rats and does not provide a direct protocol for human use.

Summary

The study shows that a traditional Japanese medicine, rikkunshito, can protect against the stomach‑slowing side effects of Parkinson's drug L‑dopa, and that this protective effect is partly blocked by a ghrelin‑blocking peptide called GHRP‑6. In rats, giving GHRP‑6 reduced the benefit of rikkunshito, suggesting GHRP‑6 interferes with ghrelin‑driven stomach motility.

Abstract

We previously reported that ghrelin prevented l-dopa (LD)-induced inhibition of gastric emptying (GE) of a non-nutrient solution in rats. Parkinson's disease treatment involves the combined administration of l-dopa with the enzyme l-amino acid decarboxylase inhibitor, carbidopa (CD) to reduce peripheral formation of dopamine. We investigated the effect LD/CD given orogastrically (og) on GE of a non-nutrient or nutrient meal and whether og pretreatment with rikkunshito, a kampo medicine clinically used to treat gastroparesis, influenced LD/CD effect on GE and postprandial antral and duodenal motility in conscious rats. LD/CD (20/2 mgkg(-1)) decreased significantly GE to 26.3 ± 6.0% compared to 61.2 ± 3.2% in og vehicle monitored 20-min after a non-nutrient meal and to 41.9 ± 5.8% compared to 72.9 ± 5.2% in og vehicle monitored 60 min after a nutrient meal. Rikkunshito (0.5 or 1.0 g kg(-1)) reduced the LD/CD (20/2 mg kg(-1)) inhibition of GE of non-nutrient meal (36.9 ± 7.4% and 46.6 ± 4.8% respectively vs. 12.1 ± 7.4% in og vehicle plus LD/CD) while having no effect alone (56.6 ± 8.5%). The ghrelin antagonist, [d-Lys(3)]-GHRP-6 (1 mg kg(-1)) injected intraperitoneally partially reversed rikkunshito preventive effect on LD/CD-inhibited GE. Rikkunshito (1.0 g kg(-1)) blocked LD/CD (20/2 mg kg(-1))-induced delayed GE of a nutrient meal and the reduction of postprandial antral motility. In 6-hydroxydopamine-induced Parkinson's disease rat model, rikkunshito (1.0 g kg(-1), og) also prevented LD/CD-inhibited gastric emptying of a nutrient meal and enhanced fasting plasma levels of acylated ghrelin. These data indicate that oral rikkunshito alleviates the delayed GE induced by LD/CD in naïve and PD rat model in part through ghrelin-related mechanisms.

Study Information

Provider

pubmed

Year

2014

Date

2014-03-11T00:00:00.000Z

DOI

10.1016/j.peptides.2014.02.011

Citations

15

References

68